Riverbridge Partners LLC now owns 458,340 shares of the company's stock worth $37,579,000 after buying an additional 321,851 shares during the period.
Several institutional investors and hedge funds have recently bought and sold shares of HSIC. Riverbridge Partners LLC boosted its position in shares of Henry Schein by 235.8% during the third quarter.
According to 16 stock analysts, Henry Schein, Inc., is being kept at an average Outperform, rating, with at least 5.87% of shares outstanding that are now legally short sold. Bowen Hanes & Co Inc claims 335,380 shares worth $27,498,000. Trust Co. of Vermont now owns 1,702 shares of the company's stock valued at $140,000 after purchasing an additional 616 shares during the last quarter. Its position was valued at $202,930,000 a decrease of 12.2% according to the filing. Finally, Davis R M Inc. boosted its position in shares of Henry Schein by 104.8% during the third quarter. Long-term investors should review current trend forecasts and yearly or five-year trend graphs to understand whether the stock is bearish or bullish or to determine whether the company is performing well. The average analysts gave this company a mean recommendation of 2.10. The stock was sold at an average price of $172.51, for a total value of $366,756.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
COPYRIGHT VIOLATION NOTICE: "Henry Schein, Inc". (NASDAQ:HSIC) that has shown a discernible change in trend levels over the path of recent market activity. If you are accessing this story on another publication, it was illegally copied and reposted in violation of USA and worldwide copyright and trademark legislation.
Shares of CF Industries Holdings, Inc.
HSIC indeed has a lot to explore for the stakeholder, as looked at the specific technical indicators that showcase the instant and chronological performances of the stock.
October 20 investment analysts at Jefferies Group LLC kept the company rating at "Hold" projecting a price of $89.00. UBS AG restated a "buy" rating on shares of Henry Schein in a research report on Friday, September 15th.
A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, November 6th. Vanguard Group Inc. now owns 8,086,317 shares of the company's stock worth $1,479,959,000 after buying an additional 236,862 shares in the last quarter. Jefferies Group LLC lowered the price target on November 7 changing the price objective from $89.00 to $74.00 and issued a "Hold" recommendation. Henry Schein has a one year low of $146.23 and a one year high of $183.00. Insiders have sold a total of 24,227 shares of company stock worth $4,200,824 in the last three months. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86.
Henry Schein, Inc. (HSIC) have shown a high EPS growth of 9.30% in the last 5 years and has earnings rose of 8.70% yoy. Henry Schein's revenue for the quarter was up 9.5% compared to the same quarter a year ago. As of the last earnings report the EPS was $3.47 with 156.95M shares now outstanding.
Moving toward the return on equity, that was booked as 19.20%, while return on assets was 7.90%. The company had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm posted $0.84 EPS.
Henry Schein announced that its board has authorized a stock buyback plan on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.